Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer
ESMO Gastrointestinal Oncology · Published 2026-07-23 · DOI 10.1016/j.esmogo.2026.100383
Free full text
Authors (11)
A. Ooki, K. Shimozaki, S. Fukuoka, S. Udagawa, K. Yoshino, K. Yoshikawa, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Ooki, A., Shimozaki, K., Fukuoka, S., et al. (2026). Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer. ESMO Gastrointestinal Oncology. https://doi.org/10.1016/j.esmogo.2026.100383
Related articles
- Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics · Japanese Journal of Clinical Oncology · 2026 · Cites or is cited by this article
- Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Early-onset biliary tract cancers: clinical and molecular insights · ESMO Gastrointestinal Oncology · 2026 · Same journal
- A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
- The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · ESMO Gastrointestinal Oncology · 2026 · Same journal
- BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · ESMO Gastrointestinal Oncology · 2026 · Same journal